Endocrine & Metabolic Disorders
ICON's endocrine and metabolic trial experience, supported by a global team of experts
Obesity and beyond
Embracing multi-indication potential during clinical development
The obesity therapeutic marketplace has rapidly embraced multi-indication drug development, following successful label expansion of incretin agonists semaglutide and tirzepatide. Explore the rise of multi-indication drug development across cardiometabolic-related conditions and the strategies driving clinical and commercial success for molecules with broad potential.
.jpeg?crop=yes&w=1017&h=1017&a=325,0&itok=f-bmM2Tc "obesity_scan_icons"){kind=icon}
Survey report
How today’s obesity developers are navigating a multi-indication landscape
From January 24 to March 5, 2025, ICON conducted a survey of 155 developers in obesity and related comorbidities. Survey respondents shared their clinical development and commercialisation strategies for molecules with broad clinical and commercial potential, and factors influencing whether or not to pursue multi-indication development of agents in their pipeline.
.jpeg?crop=yes&w=1251&h=1251&a=399,0&itok=z3hEpdQt "obesity scan person"){kind=icon}
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year because of the disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ICON survey report:
Trends and challenges in obesity research and clinical trials
Explore the ICON survey of global industry professionals currently engaged in obesity-related clinical research. Respondents were from organisations ranging from small biotechs to large pharmaceutical companies, as well as academic organisations. The survey was designed to measure industry opinions on trends and challenges for the sector.
Webinar: Addressing the challenges of Type 2 Diabetes global clinical trials via high quality lab solutions
Join ICON’s expert Dr. Andrew Roche, PhD as he speaks about overcoming challenges when developing Diabetes trials. Addressing these challenges via use of high quality tools is critical to successful completion of a clinical trial.
Webinar: Digital solutions to alleviate NASH clinical trial challenges
Find out more about the ability for digital technologies including magnetic resonance imaging (MRI), magnetic resonance elastography (MRE) and whole slide imaging (WSI) to address NASH clinical trial challenges.
Endocrine and metabolic disorders blogs and media contributions
-
.jpeg?crop=yes&w=545&h=286&itok=G5k539TI "obesity scan person")
Press release: Global ICON survey shows need for more efficient obesity clinical trial design
ICON plc today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
Media article: The challenge of targeting chronic inflammation in obesity
In this article, ICON experts explore the connection of obesity and inflammation, the current treatment landscape and future treatment directions.
-
Media article: Expanding diagnostic and biomarker options to improve MASH clinical trials
The absence of sufficient and accessible diagnostics for metabolic dysfunction-associated steatohepatitis (MASH) studies can complicate trials and impair clinical study conduct, as diagnostics are essential for disease detection, confirmation, and monitoring.
-
Blog: Obesity-related liver conditions: Understanding treatment options
Explore obesity’s role in liver disease progression and the value of different treatment options providing renewed hope to patients.
-
Blog: Designing clinical trials for a complex disease: Pediatric obesity
Pediatric obesity is a complex disease with multiple factors for sponsors to consider when designing and executing treatment trials.
-
Blog: A dynamic market: Trends transforming the future of obesity drug development
Learn about the future of obesity drug development and explore how GLP-1 drugs and multi-indication therapies are transforming treatment.
-
Media article: Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
Media article: Liver disease, obesity and the value of treatment
The link between obesity and metabolic-dysfunction associated steatotic liver disease (MASLD), and touches on recent advancements in effective treatments for obesity.
.jpeg?crop=yes&w=2048&h=1077&a=0,88&itok=wmM4vNHA "obesity scan person"){kind=icon}
Endocrine & Metabolic Disorders services
ICON is an experienced partner who can assist sponsors in navigating the many challenges of endocrine & metabolic disorders drug development. ICON can help sponsors optimise the clinical trial lifecycle from patient enrolment to payer reimbursement with its customisable solutions and proven strategies. Our highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including, diabetes, cardiometabolic disorders, gastroenterology, and hepatology.